Treatment Initiation, Substance Use Trajectories, and the Social Determinants of Health in Persons Living With HIV Seeking Medication for Opioid Use Disorder

Overview

Journal Subst Abus

Publisher Sage Publications

Specialties Medical Education
Psychiatry

Date 2023 Oct 16

PMID 37842910

Authors

Ryan R Cook

Erin N Jaworski

Kim A Hoffman

Elizabeth N Waddell

Renae Myers

P Todd Korthuis

Pamela Vergara-Rodriguez

Affiliations

Soon will be listed here.

Abstract

Background: People living with HIV and opioid use disorder (OUD) are disproportionally affected by adverse socio-structural exposures negatively affecting health, which have shown inconsistent associations with uptake of medications for OUD (MOUD). This study aimed to determine whether social determinants of health (SDOH) were associated with MOUD uptake and trajectories of substance use in a clinical trial of people seeking treatment.

Methods: Data are from a 2018 to 2019 randomized trial comparing the effectiveness of different MOUD to achieve viral suppression among people living with HIV and OUD. SDOH were defined by variables mapping to Healthy People 2030 domains: education (Education Access and Quality), income (Economic Stability), homelessness (Neighborhood and Built Environment), criminal justice involvement (Social and Community Context), and recent SUD care (Health Care Access and Quality). Associations between SDOH and MOUD initiation were assessed with Cox proportional hazards models, and SDOH and substance use over time with generalized estimating equation models.

Results: Participants (N = 114) averaged 47 years old, 63% were male, 56% were Black, and 12% Hispanic. Participants reported an average of 2.3 out of 5 positive SDOH indicators (SD = 1.2). Stable housing was the most commonly reported SDOH (61%), followed by no recent criminal justice involvement (59%), having a high-school level education or greater (56%), income stability (45%), and recent SUD care (13%). Each additional favorable SDOH was associated with a 25% increase in the likelihood of MOUD initiation during the study period [adjusted HR = 1.25, 95% CI = (1.01, 1.55), = .044]. Positive SDOH were also associated with a decrease in the odds of baseline opioid use and a greater reduction in opioid use during subsequent weeks of the study ( < .001 for a joint test of baseline and slope differences).

Conclusions: Positive social determinants of health, in aggregate, may increase the likelihood of MOUD treatment initiation among people living with HIV and OUD.

References

Chang M, Moonesinghe R, Schieber L, Truman B . Opioid-Related Diagnoses and Concurrent Claims for HIV, HBV, or HCV among Medicare Beneficiaries, United States, 2015. J Clin Med. 2019; 8(11). PMC: 6912616. DOI: 10.3390/jcm8111768. View

Spears C, Taylor B, Liu A, Levy S, Eaton E . Intersecting epidemics: the impact of coronavirus disease 2019 on the HIV prevention and care continua in the United States. AIDS. 2022; 36(13):1749-1759. DOI: 10.1097/QAD.0000000000003305. View

Tuten M, DeFulio A, Jones H, Stitzer M . Abstinence-contingent recovery housing and reinforcement-based treatment following opioid detoxification. Addiction. 2011; 107(5):973-82. PMC: 3421907. DOI: 10.1111/j.1360-0443.2011.03750.x. View

Fanucchi L, Springer S, Korthuis P . Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. Curr HIV/AIDS Rep. 2019; 16(1):1-6. PMC: 6420833. DOI: 10.1007/s11904-019-00436-7. View

Mauro P, Gutkind S, Annunziato E, Samples H . Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019. JAMA Netw Open. 2022; 5(3):e223821. PMC: 8943638. DOI: 10.1001/jamanetworkopen.2022.3821. View

Tsui J, Akosile M, Lapham G, Boudreau D, Johnson E, Bobb J . Prevalence and Medication Treatment of Opioid Use Disorder Among Primary Care Patients with Hepatitis C and HIV. J Gen Intern Med. 2021; 36(4):930-937. PMC: 8041979. DOI: 10.1007/s11606-020-06389-7. View

Taylor J, Johnson S, Cruz R, Gray J, Schiff D, Bagley S . Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment. J Gen Intern Med. 2021; 36(12):3810-3819. PMC: 8218967. DOI: 10.1007/s11606-021-06904-4. View

Sulley S, Ndanga M . Inpatient Opioid Use Disorder and Social Determinants of Health: A Nationwide Analysis of the National Inpatient Sample (2012-2014 and 2016-2017). Cureus. 2020; 12(11):e11311. PMC: 7714736. DOI: 10.7759/cureus.11311. View

Saloner B, Whitley P, LaRue L, Dawson E, Huskey A . Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database. JAMA Netw Open. 2021; 4(9):e2123019. PMC: 8433604. DOI: 10.1001/jamanetworkopen.2021.23019. View

10.

Godley B, Adimora A . Syndemic theory, structural violence and HIV among African-Americans. Curr Opin HIV AIDS. 2020; 15(4):250-255. DOI: 10.1097/COH.0000000000000634. View

11.

Frost M, Lampert H, Tsui J, Iles-Shih M, Williams E . The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review. Addict Sci Clin Pract. 2021; 16(1):62. PMC: 8504567. DOI: 10.1186/s13722-021-00266-2. View

12.

Susukida R, Crum R, Stuart E, Ebnesajjad C, Mojtabai R . Assessing sample representativeness in randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network. Addiction. 2016; 111(7):1226-34. PMC: 4899104. DOI: 10.1111/add.13327. View

13.

Englander H, King C, Nicolaidis C, Collins D, Patten A, Gregg J . Predictors of Opioid and Alcohol Pharmacotherapy Initiation at Hospital Discharge Among Patients Seen by an Inpatient Addiction Consult Service. J Addict Med. 2019; 14(5):415-422. PMC: 7954140. DOI: 10.1097/ADM.0000000000000611. View

14.

Wyse J, Robbins J, McGinnis K, Edelman E, Gordon A, Manhapra A . Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. Drug Alcohol Depend. 2019; 198:70-75. PMC: 6836871. DOI: 10.1016/j.drugalcdep.2019.01.038. View

15.

Perlman D, Jordan A . The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions. Curr HIV/AIDS Rep. 2018; 15(2):96-112. PMC: 5884743. DOI: 10.1007/s11904-018-0390-3. View

16.

Blue T, Gordon M, Schwartz R, Couvillion K, Vocci F, Fitzgerald T . Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine. Addict Sci Clin Pract. 2019; 14(1):45. PMC: 6886176. DOI: 10.1186/s13722-019-0172-2. View

17.

Trivedi M, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T . Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021; 384(2):140-153. PMC: 8111570. DOI: 10.1056/NEJMoa2020214. View

18.

Strickland J, Stoops W, Dunn K, Smith K, Havens J . The continued rise of methamphetamine use among people who use heroin in the United States. Drug Alcohol Depend. 2021; 225:108750. PMC: 8282713. DOI: 10.1016/j.drugalcdep.2021.108750. View

19.

Parlier-Ahmad A, Radic M, Svikis D, Martin C . Short communication: Relationship between social determinants and opioid use disorder treatment outcomes by gender. Drug Alcohol Depend. 2022; 232:109337. PMC: 8885974. DOI: 10.1016/j.drugalcdep.2022.109337. View

20.

Swartz N, Adnan T, Perea F, Baggett T, Chatterjee A . "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness. J Subst Abuse Treat. 2022; 138:108752. DOI: 10.1016/j.jsat.2022.108752. View